CSBio CSBio

X
[{"orgOrder":0,"company":"TWi Biotechnology","sponsor":"Winhealth Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Winhealth Pharma and TWiB Enter into Strategic Licensing Partnership on AC-203","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"TWi Biotechnology"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Strategic partnership grants Winhealth Pharma exclusive right to develop and commercialize rare disease asset AC-203 in mainland China, Hong Kong and Macao for indications including hereditary epidermolysis bullosa (EB), bullous pemphigoid and other skin diseases.

            Lead Product(s): CAS 139481-59-7

            Therapeutic Area: Genetic Disease Product Name: AC-203

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Winhealth Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership January 06, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY